Randomised Controlled Trial on the efficacy of Mamajjaka (Enicostemma littorale Linn.) in the Management of Madhumeha (Diabetes Mellitus)

Diabetes Mellitus is in top ten list of diseases causing mortality. In the year 2011, estimated 366 million people were found to be suffering from diabetes mellitus. By year 2030 this morbidity data will rise to approximately 552 million people worldwide. India is having the largest number of diabetics in the world and gets the name ‘Diabetic capital’. This study was carried out with an aim:-‘To Conduct a Randomised Controlled (Upashayatmaka) Trial on the role of Mamajjaka capsule in the management of Madhumeha (DM type-2)’. In this study total 110 patients of Diabetes were selected from NIA hospital and randomly divided into two groups. Group A (Control group) comprise 54 patients were administered with Tab. Metformin and dose was 500mg tablet 1 BD before meals as advised according to allopathic consultant. Group B (Trial group) comprise 56 patients were administered with Cap. Mamajjaka, dose: 500 mg Capsule 2 BD, before 30 min. of meal with lukewarm water. Total duration trial was 100 days. Results obtained in subjective and objective parameters were analysed for the statistical significance by adapting paired T test and unpaired T test. The study revealed that Group-B was found to be more effective in bringing symptomatic relief and Group-A was found to be more effective in improving biochemical markers in the patients of Madhumeha. Cap. Mamajjaka (Enicostemma littorale Linn.) provided better results, suggests that this can be a good complimentary medicine for the patients who are not getting good relief from modern medicine alone.